International Clinical Trial: Irinotecan liposomes combined with Sindilizumab in second-line and later patients with advanced gastric cancer: a prospective, single-center, single-arm Phase II clinical study

Geneva, Feb. 13 -- International Clinical Trials Registry received information related to the study (ChiCTR2600118190) titled 'Irinotecan liposomes combined with Sindilizumab in second-line and later patients with advanced gastric cancer: a prospective, single-center, single-arm Phase II clinical study' on Feb. 3.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Hubei Cancer Hospital

Condition: gastric cancer

Recruitment Status: Recruiting

Phase: 2

Date of First Enrollment: 2025-03-24

Target Sample Size: experimental group:44;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=270149

Disclaimer: Curated by HT Syndication....